were evaluated by microarray, quantitative RT-PCR (qRT-PCR), Cell Counting Kit-8(CCK-8) assay, glucose assay, lactate assay, transmission electron microscopy, as well as Western blot analysis. Dualluciferase reporter assay was used to identify the relationship between miR-361-5p, SP1, and PKM2.
INTRODUCTION AND OBJECTIVES: Solute carrier organic anion (SLCO) genes encode organic anion transport proteins, which is a family of transport proteins that influx number of substrates into the cells including androgens. Among them, high expression of SLCO genes, including SLCO1B3 and SLCO2B1, has been shown to be associated with the resistance to androgen deprivation therapy in prostate cancer. However, the significance of the expression of SLCO genes in the recurrence after radical prostatectomy has not been elucidated. Here, we hypothesized that the high expression of these SLCO genes in human prostate cancer is associated with the recurrence after radical prostatectomy.
METHODS: Clinical and RNA-seq data were all obtained from the Cancer Genome Atlas (TCGA). Patients were classified as either high or low expression of SLCO1B3 or SLCO2B1 by the mean value. Survival analysis and gene set enrichment analysis (GSEA) was conducted between high and low expression group in whole cohort, as well as by Gleason score (GS¼6, ¼7 or ¼8).
RESULTS: Patients were classified with the expression level of SLOC1B3 or SLCO2B1 by mean value of each gene. In overall survival, either of these genes was not related to survival. However, high expression group of SLCO2B1 showed significantly worse disease-free survival after radical prostatectomy (p¼0.026), whereas the expression level of SLCO1B3 was not related to disease-free survival. The patients with higher Gleason score had significantly higher levels of SLCO2B1 expression (GS<6 vs GS¼7; p¼0.045, GS¼7 vs GS>8; p¼0.002). Significant difference in disease-free survival between high and low expression groups were only observed in the patients with GS¼8 (p¼0.005), and not in the patients with GS¼7 (GS<6; p¼0.640, GS¼7; p¼0.923). GSEA demonstrated that in the high expression group of SLCO2B1 enriched epithelial mesenchymal transition signaling related genes.
CONCLUSIONS: High expression of SLCO2B1 in the prostate cancer patients associated with the aggressive cancer characteristics and recurrence after radical prostatectomy, however no relation was found with the expression level of SLCO1B3. Furthermore, the high recurrence rate of the patients with high expression of SLCO2B1 may be able to be explained by its metastatic potential with up-regulated EMT pathways.
Source of Funding: none

MP64-05 THE APPLICATION OF MINIMAL SCORE OF APPARENT DIFFUSION COEFFICIENT (ADC) IN PROSTATE MRI TO PREDICT THE PROSTATE CANCER MICROENVIRONMENT
Manabu Kato*, Tsu, Japan; Placencio Veronica, Los Angeles, CA; Kenichiro Ishii, Kohei Nishikawa, Kiminobu Arima, Yoshihumi Hirokawa, Masatoshi Watanabe, Yoshiki Sugimura, Tsu, Japan INTRODUCTION AND OBJECTIVES: Multi-parametric MRI and the mapping with Apparent Diffusion Coefficient (ADC) reinforce the accuracy for local detection of prostate cancer. It has been hard to predict the conditions of tumor microenvironment before the treatment. In this prostate tumor microenvironment, cancer-associated fibroblasts plays important role for cancer progression and invasion, and these components shows tendency of high expression for specific protein markers including Vimentin, CD105 and TNC-C. On the other hand, aSMA is commonly used as a marker of smooth muscle cells and expressed in the stroma area surrounding normal prostate grounds. In this study, we examined the MRI predictive availability for evaluation of prostate cancer microenvironment by comparing the pre-operation MRI images with the findings of immunohistochemistry (IHC) of prostate cancer surgical specimens. Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e851 METHODS: 44 cases were analyzed that are surgically operated with robot-assisted radical prostatectomy performed from February to September in 2016. Preoperative MRI have been conducted for all 44 cases, and the prostate cancer local diagnoses (Region of Interest: ROI) were determined by radiologists using MRI T2 weighed image and Diffusion Weighed Image (DWI), then finally the scores of ADC were calculated. IHC for aSMA, vimentin, CD105, and Tenascin-C (TNC-C) were conducted and classified into three group (none stained, weakly stained, strongly stained) to check the relation of those IHC findings to MRI ADC score before the treatment.
RESULTS: The average of minimum ADC scores in ROC of these prostate cancer patients before surgery was 0.779 (SD¼0.173). IHC comparison were made according to the cut off value of the minimum ADC scores between more (n¼18, group A) and less (n¼26, group B) than 0.800. 66% (12/18) patients showed strongly stained findings for aSMA in group A. Meanwhile, vimentin, CD105, and TNC-C showed strong stained in B group, 22.2% (4/18) and 61.5% (16/26), 22.2% (4/18) and 0% (0/26), and, 33.3% (6/18) and 76.9% (20/26) in group A and B, respectively. (Conclusions) CONCLUSIONS: To use these multi-parametric MRI findings, especially pretreatment ADC scores, our results suggested postoperative IHC findings and more to address, tumor microenvironment could be predicted. The more various treatment selection have been and could be applied to prostate cancer, such as upfront chemotherapy and wide resection for surrounding tissues, the more precise procedure are needed to predict tumor microenvironment in order to detect potentially aggressive prostate cancer.
Source of Funding: None
MP64-06 BIOINFORMATIC ANALYSIS IDENTIFIED CANDIDATE DRUGS FOR ANDROGEN SIGNALING THROUGH MODULATING ANDROGEN RECEPTOR AND ITS SPLICE VARIANTS
Hiroshi Hongo*, Takeo Kosaka, Yota Yasumizu, Yasumasa Miyazaki, Eiji Kikuchi, Mototsugu Oya, Shinjuku-ku, Japan INTRODUCTION AND OBJECTIVES: The efficacy of various next-generation antiandrogens for CRPC is limited. In this study, we investigated gene expression profiles of CRPC cells with AR knockdown using microarray, and identified candidate drugs for overcoming CRPC through degrading AR splice variants.
METHODS: Three cell lines were used: LNCaP, a human PCa cell line that exhibits androgen-dependent proliferation; C4-2AT6, an androgenindependent CRPC cell line; and 22Rv1 an AR-V7 positive CRPC cell line. Gene expression change by AR knockdown in CRPC cells were analyzed using a microarray and compared using CMAP to identify a candidate drug with the potential to have AR degradation effect similar to AR knockdown. The efficacy of the candidate drug was tested in vitro and in vivo.
RESULTS: We investigated and compared the viability of prostate cancer cells treated with DHT. DHT promoted LNCaP cells proliferation in dose dependent manner. On the other hand, C4-2AT6 cells showed significantly decreased cell viability when treated with DHT. We next perform AR knockdown by SiRNA to LNCaP and C4-2AT6. In WST assay, relative cell viability after AR knockdown was 46.9 % AE 2.7 % and 44.1 AE 2.0 %, respectively. These results suggested that C4-2AT6 depended on AR signaling while it had androgen independence We explored candidate drugs which mimicked AR knockdown to C4-2AT6 by CMAP analysis. We identified a candidate compound for degrading AR in CRPC, AHG113. The cytotoxic effect of AHG113 was investigated by a cell viability assay in LNCaP and C4-2AT6 cells; relative cell viability when treated with 10 mM AHG113 was 79.2 AE 1.1 % and 67.5 AE 1.9 %, respectively. AHG113 was suggested to have higher cytotoxicity to CRPC than androgen dependent PCa (p ¼ 0.002). Western blotting demonstrated AHG113 degrade AR protein in C4-2AT6. Because AR-V7 was focused as a next-generation antiandrogens resistance mechanism, we investigated AR-V7 degradation effect of AHG113. Western blotting and flow cytometry demonstrated AHG113 degraded both AR full length and AR-V7 in 22Rv1. We administered AHG113 to 22Rv1 xenograft mice for investigating anti-tumor effect in vivo. AHG113 significantly inhibited xenograft tumor growth (p < 0.001). Immunohistochemistry of xenograft tumor demonstrated AHG113 reduced AR-V7 expression.
CONCLUSIONS: AHG113 may be promising drug for overcoming androgen-independent and AR-V7 positive CRPC.
Source of Funding: This work was supported by JSPS KAKENHI Grant Number 17K16813 to Hongo H, and 25861451 to Kosaka T from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
INTRODUCTION AND OBJECTIVES: It's accepted that angiogenesis is a complex phenomenon accompanying the development, progression and metastasis of tumors of unrelated histological origin. We introduce the Hurst index to investigate the two-dimensional (2-D) geometrical complexity of the tumor vascular network in biopsy specimens to comprehend whether non-tumoral biopsy cores might be helpful to select patients with hidden prostate cancer.
METHODS: 1984 biopsy cores sampled from a total of 316 patients were analyzed. Patients were categorized in two main groups: a) Prostate Cancer Group: 140 patients with first positive biopsies for prostate cancer and 60 patients negative for prostate cancer at first biopsy and positive at re-biopsy. b)
